Clinical Trials
Catherine Curtin, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
Dyani Gaudilliere, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
David Kahn, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
Gordon Lee, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
H. Peter Lorenz, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
Arash Momeni, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested
Dung Nguyen, MD
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Are willing and able to provide informed consent
2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands
in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
3. Are willing and able to adhere to the protocol and long-term follow-up
Exclusion Criteria:
1. Subjects unwilling or unable to meet with the requirements of the study will be excluded
Ages Eligible for Study
18 Years - 81 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Somayeh H. Ahmad
650-441-0405
I'm interested